Contract Manufacturing Dependency Board Challenger — Consumer Health

The mandate

Portfolio growth depends on six contract manufacturers that hold formula know-how, validated tooling, local registrations and surge capacity not easily reproduced elsewhere. Management reports supplier performance and dual-source counts, but the board cannot see which alternatives are technically qualified, economically viable or available during a simultaneous category surge. Recent ownership changes at two partners sharpen the standing dependency question.

Four days each month cover one document review, two management or partner-evidence sessions and one committee preparation or attendance day; five formal committee meetings are included. The challenger will answer urgent board questions on a proposed volume commitment or partner event within four business days. Each cycle must connect commercial growth proposals with real transfer lead times and dependency retirement.

The appointment runs nine months through approval of the next outsourced-manufacturing strategy. The committee may request one additional month solely if a disclosed partner change-of-control occurs after the final scheduled evidence session. Any continuation needs a fresh statement of unresolved dependency, reviewed interests and explicit chair approval; no automatic renewal attaches to ongoing supplier monitoring.

The adviser has no line authority and assumes no executive responsibility for supply, quality, procurement, product transfer, partner negotiation, regulatory affairs or investment. Executives select and manage manufacturers; Quality approves regulated activity; the board decides material commitments. The challenger may question resilience claims and recommend evidence gates but cannot contact a partner independently, award volume or instruct a transfer.

Current roles with competing consumer-health companies, contract manufacturers, private-equity owners, transfer specialists or critical ingredient suppliers must be disclosed. Success fees and undisclosed portfolio exposure are incompatible. The scope excludes tender evaluation, quality auditing, technical due diligence, contract negotiation, site assurance, product registration and direct participation in sourcing decisions.

Why the board wants this voice

Management’s supplier scorecards describe performance inside the current model, while directors must decide whether the model itself creates concentrated technical and negotiating exposure. The board wants an operator who has exited and transferred outsourced production to test asserted alternatives without becoming a shadow procurement or Quality function.

What you will own

• Press directors on where formula knowledge, tooling, licences, data, people and surge options reside outside company control.
• Test each stated second source for technical equivalence, validated capacity, economics, lead time and regulatory usability.
• Challenge volume commitments that improve price while narrowing exit rights, flexibility or access to critical evidence.
• Examine partner ownership, financial health, competing customers and geographic concentration as linked operational exposures.
• Trace portfolio growth cases into transfer capacity, quality oversight, working capital and business-continuity assumptions.
• Maintain a board ledger of unproven alternatives, dependency thresholds, expiring mitigations and management commitments.
• Probe a simultaneous demand surge, partner sale, quality hold and critical-ingredient allocation scenario.

Candidate qualifications

• Advised boards or led external manufacturing across consumer health, pharmaceuticals, food or regulated personal care.
• Executed contract-manufacturer transfers involving proprietary process knowledge, validated tooling and registration constraints.
• Distinguished nominal dual sourcing from technically qualified, economically defensible and contractually accessible alternative production capacity.
• Challenged supplier concentration while respecting Quality, Regulatory, procurement and executive decision boundaries.
• Evaluated material change-of-control and competing-customer exposure without acting as transaction or legal adviser.
• Maintained independence from manufacturers, owners, ingredient suppliers and service firms relevant to reviewed decisions.

Non-negotiables

• Available four days monthly for Copenhagen sessions, five committees and six partner-dependency examinations.
• Direct external-manufacturing governance is required; procurement category management alone is insufficient.
• Will disclose consumer-health, manufacturer, investor, supplier, transfer and regulatory-advisory interests before appointment.
• Will not audit quality, negotiate contracts, award volume, direct transfers, evaluate tenders or contact partners uninvited.

1. 49 words maximum. Describe a nominal second source that proved unusable during an actual supply event.
2. 49 words maximum. Which manufacturer, investor or consumer-health interests would require disclosure here?
3. 49 words maximum. How would you test a partner change-of-control scenario within four board days monthly?